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INTRODUCTION
Endoscopic therapies such as injections, clipping, and thermal 
ablation have been effective in achieving primary hemostasis 
in patients with non-variceal upper gastrointestinal hemorrhage 
(NGIH).1 Despite these advancements in therapeutic endosco-
py, bleeding recurs in 15-20% of cases after successful endoscopic 
therapy for NGIH.2 Moreover, NGIH remains a common cause 
of hospitalization and rebleeding, which are the most important 
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predictive factors of mortality, occurring in 3.1-7.0% of patients.3-5 
Therefore, prevention and prediction of patients at risk of re-
bleeding, after initial endoscopic therapy, is essential for a suc-
cessful outcome in patients with NGIH.
The presence of large ulcers (≥1 cm) with severe bleeding 
at presentation is well known to be predictive of rebleeding.4,6 
Proton pump inhibitor (PPI) has been reported as an effective 
medication for recurrent bleeding after endoscopic therapy.7,8 
In addition, advanced age, comorbidity, shock, rebleeding, and 
the need for surgery have been associated with an increase in 
mortality after endoscopic hemostasis.8,9 However, little is known 
about additional risk factors for rebleeding after endoscopic 
therapy, although scoring systems have been developed for the 
prediction of outcomes in patients with NGIH.10 Therefore, iden-
tification of the factors related to the development of rebleeding, 
after endoscopic therapy for NGIH, might improve patient 
management and outcome. The aim of this study was to evalu-
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ate the clinical outcome and potential predictive factors associ-
ated with rebleeding in patients undergoing endoscopic thera-
py for NGIH.
MATERIALS AND METHODS
Patients
Between January 2003 and January 2007, a total of 554 bleed-
ing events in 487 patients (M:F=366:121; Age, 58.9±15.3) who 
underwent endoscopic therapy for NGIH were retrospectively 
enrolled. Patients that were not treated with endoscopic thera-
py or had Mallory-Weiss syndrome were excluded. The clinical 
and endoscopic characteristics of patients with rebleeding were 
reviewed and compared with patients who did not develop re-
bleeding. Patient characteristics and rebleeding related data were 
recorded for the following variables: gender, age, alcohol and 
smoking history, underlying disease (chronic renal failure, liver 
cirrhosis, hypertension without aspirin use, diabetes mellitus, 
aspirin or clopidogrel use, current use of coumadin, and others), 
past gastrointestinal bleeding history, endoscopic findings (cause 
and location of bleeding, size, and bleeding state), endoscopic 
therapies, endoscopists’ experiences, clinical outcomes, and mor-
tality. A written informed consent for therapy was obtained from 
each patient. The study was carried out in accordance with the 
Helsinki Declaration after the approval of Institutional Review 
Board of Wonju Christian Hospital.
All patients were managed according to NIGH treatment pro-
tocol of the hospital. The patients’ vital signs were assessed at 10 
minutes interval before the endoscopy, and then every 2 hours 
for 24 hours after the endoscopy, and every 6 hours thereafter 
until the follow-up after the endoscopy. The hemoglobin level 
was checked at least once daily; a blood transfusion was given 
if the hemoglobin level decreased to lower than 9 g/dL. Rebleed-
ing was defined by at least two of the followings: new-onset he-
matemesis or melena with blood pressure <100 mm Hg, decrease 
of more than 2 g/dL in hemoglobin level, endoscopic confirma-
tion of bleeding, or pathologic lesion which required endoscopic 
therapy within 7 days after the initial therapy. Bleeding state 
was classified by Forrest classification (Fig. 1): active spurting 
bleeding (Ia), active oozing bleeding (Ib), vessel exposure (IIa), 
and red or black adherent clots (IIb).
 
Endoscopic therapy
All feasible patients presented to the hospital with NGIH un-
derwent endoscopy within 24 hours. The patients received in-
travenous PPIs to promote healing of the lesion before and af-
Fig. 1. Bleeding status. (A) Active pumping. (B) Active oozing. (C) Vessel exposure. (D) Red or black clot.
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ter the endoscopic therapy. Levin tube insertion and irrigation 
with more than 3,000 cc of normal saline was provided before 
the initial endoscopy. Thirteen gastroenterologists, with more 
than 2 years of experience (>6,000 cases of endoscopy) of per-
forming endoscopy, carried out the therapeutic endoscopy for 
NGIH during the study period. Therapies used for the initial 
NGIH were 1:10,000 epinephrine injection, GLUE (throm-
bin/fibrin, Greenplast; Green Cross, Yongin, Korea) injection, 
hemoclipping, and thermal ablation (monopolar or argon plas-
ma coagulation [APC]). Patients were scheduled to have a fol-
low-up endoscopy within 24 hours. If the general condition was 
not suitable for an endoscopy, the follow-up endoscopy was de-
layed. After evaluation of the follow-up endoscopy, further man-
agement was decided including: the appropriate meal time, fol-
low-up endoscopic therapy, endoscopic biopsy, and Helico-
bacter pylori test. If active bleeding or vessel exposure was 
observed at the follow-up endoscopy, it was considered as a 
rebleeding and a second session of endoscopic therapy was 
planned (Fig. 2). If the bleeding continued after the endoscop-
ic therapy, surgery or embolization therapy was performed. Dur-
ing fasting periods, 40 mg of intravenous pantoprazole sodium 
was injected, as a bolus, every 12 hours. And then, all patients 
were treated with oral PPI at a standard dose every morning dur-
ing the next 6-8 weeks. Patients with positive rapid urea test re-
sults were provided with 7-day eradication therapy (10 mg or 20 
mg of PPI+1 g of amoxicillin+500 mg of clarithromycin, b.i.d.). 
Patients underwent blood test, abdominal ultrasound, and a 
routine abdominal X-ray during the admission and on an out-
patient basis after the procedure to assess bleeding, perforation, 
or other possible complications.
Statistical analysis
An independent-samples t-test was used for comparison of 
continuous variables. Data were expressed as means and stan-
dard deviations. The correlation between rebleeding and risk vari-
ables was assessed by univariate analysis. In addition, multivari-
ate logistic regression analysis was performed to identify factors 
related to rebleeding and mortality. Age, gender, and plausible 
risk factors (p<0.25) from the results of the univariate analysis 
were used in the multivariate analysis where appropriate. The 
enter method was performed to find the odds ratios; and the 
relationship of each variable in the multivariate analysis was an-
alyzed. Data were analyzed with statistical software (SPSS ver-
sion 13.0; SPSS Inc., Chicago, IL, USA). A p-value <0.05 was 
considered significant in all tests.
RESULTS
Patient characteristics and clinical outcomes of re-
bleeding
The mean age of the patients was 59.1 years (range, 13-93 
years). Among a total of 554 patients, 120 (21.7%) patients were 
A  
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Fig. 2. Serial endoscopic findings show rebleeding after the initial endoscopic therapy. (A) Initial endoscopic finding. (B) Post state of epi-
nephrine injection+argon plasma coagulation. (C) Rebleeding occurred 2 days after the initial endoscopic treatment. (D) Second endoscop-
ic therapy with epinephrine injection+argon plasma coagulation. (E) Post state of second endoscopic therapy.
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diagnosed as rebleeding after the endoscopic therapy. The causes 
of NGIH were gastric ulcer in 327 (59.1%), duodenal ulcer in 173 
(31.2%), Dieulafoy lesion in 26 (4.7%), marginal ulcer in 16 
(2.9%), and cancer bleeding in 12 (2.2%) patients. Comorbid 
diseases and medications used included chronic renal failure 
in 70 (12.6%), aspirin or clopidogrel use in 68 (12.3%), liver cir-
rhosis in 61 (11.0%), hypertension without aspirin therapy in 
50 (9.0%), diabetes mellitus in 25 (4.5%), current use of couma-
din in 25 (4.5%), diabetes mellitus and hypertension without as-
pirin therapy in 17 (3.1%), and others in 8 (1.4%) patients. The 
remaining (229 patients) had no underlying disease. The aver-
age hospital stay was 12 days (range, 1-210 days) after the endo-
scopic therapy. Twenty patients (3.6%) underwent surgery and 1 
patient was treated with embolization because of continuous 
bleeding after therapy. Forty-four patients (7.9%) died after the 
endoscopic therapy (Table 1).
With regard to endoscopic characteristics (Table 2), the bleed-
ing was characterized by vessel exposure in 257 (46.4%), active 
oozing in 179 (32.3%), active spurting bleeding in 48 (8.7%), and 
red and black clots in 70 (12.6%) patients. APC therapy (18.6%) 
was most commonly used as a single therapy. The mean amount 
of epinephrine used in therapy was 13.5 (12.8) cc. In the com-
bination therapy, epinephrine and GLUE (Greenplast) injection 
therapy (22.4%) was the most common combination therapy in 
this study. The mean ulcer size was 13.6 (10.2) mm. The mean 
therapeutic experience of the endoscopist was 3.7 (3.0) years. In 
the gastric lesions, most common locations of bleeding were the 
body and lesser curvature.
Factors related to rebleeding 
The univariate analysis showed no significant differences in 
gender, age, alcohol and smoking history, previous bleeding his-
tory, international normalized ratio, cause of bleeding, size of 
ulcer, and the number of biopsy in the rebleeding group com-
pared to the group without rebleeding. However, lower initial 
hemoglobin level and platelet count (p=0.010 and p=0.009), 
comorbidity with chronic renal disease (p=0.000), degree of 
initial bleeding state (p=0.010), endoscopic treatment modality 
(p=0.002), experience of the endoscopist (p=0.002), and the 
need for large amount (>15 cc) of epinephrine during the thera-
py (p=0.000), were found to be positively related to rebleeding 
(Tables 1, 2).
In the multivariate analysis, initial hemoglobin level ≤9 g/dL 
(p=0.002; odds ratio [OR], 2.433), unskillful endoscopist with 
Table 1. Clinical Characteristics of Patients
Characteristic Rebleeding (n=120) No rebleeding (n=434) p-value
Gender, male/female 98/22 329/105 0.219
Age, yr 59.4±13.3 59.1±15.6 0.842
Alcohol history, yes/no 74/46 237/196 0.212
Smoking history, yes/no 67/53 229/204 0.135
Previous bleeding history, times 1.1±0.3 1.1±0.4 0.771
Initial SBP, mm Hg 115±29 117±260 0.520
Initial DBP, mm Hg 72±16 72±15 0.676
Initial heart rate/min 94±18 91±19 0.091
Laboratory findings
Hemoglobin, g/dL 8.5±2.5 9.2±2.8 0.010
Platelet, 109/L 209±150 241±112 0.009
INR 1.2±0.4 1.2±1.0 0.597
Comobid diseases 0.000
No specific disease or medication 53 (44) 277 (64)0
Chronic renal failure 27 (23) 43 (10)
Liver cirrhosis 18 (15) 43 (10)
Coumadin use 7 (6) 18 (4)0
Aspirin or clopidogrel use 15 (13) 53 (12)
Meal day after endoscopic therapy 5.5±6.2 2.2±3.5 0.000
Admission days after endoscopic therapy 17.6±15.5 10.5±18.4 0.000
Survival 96 (80) 415 (96)0 0.000
Values are presented as mean±SD or number (%); p-value for Pearson’s χ2 test (2 by 2 and 2 by x) and the independent-samples t-test for com-
parison of continuous variables.
SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; INR, international normalized ratio.
KT Suk et al. 
  97
less than 2 years of therapeutic endoscopy experience (p=0.001; 
OR, 2.418), the need for more 15 cc of epinephrine (p=0.001; 
OR, 2.570), injection therapy compared to thermal and injec-
tion therapy (p=0.001; OR, 2.840), and comorbidity with chron-
ic renal disease (p=0.004; OR, 2.908) or liver cirrhosis (p=0.010; 
OR, 2.870) were risk factors of rebleeding following endoscopic 
therapy. Initial active spurting bleeding (p=0.021; OR, 5.208) 
and rebleeding (p=0.000; OR, 6.391) were significantly relat-
ed to mortality (Table 3).
Factors related to mortality  
The mortality rate of patients without comorbid disease (7.0%, 
n=23) was lower than that of patients with chronic renal disease 
(17.1%, n=12) or liver cirrhosis (11.5%, n=7). In the univariate 
analysis, the mortality rate was significantly higher in patients 
with advanced age, history of alcohol consumption, location of 
bleeding in the body, the presence of rebleeding or surgery, the 
need for large amounts of epinephrine, low blood pressure or 
platelet count at presentation, fast heart rate on presentation, ac-
tive bleeding, and a longer hospitalization (p<0.05). 
The multivariate analysis showed that initial active spurting 
bleeding (p=0.021; OR, 5.208) and rebleeding (p=0.000; OR, 
6.391) were significantly related to the mortality following the 
endoscopic therapy (Table 4). 
DISCUSSION
In this study, the frequency of rebleeding after the initial en-
doscopic therapy was 22.1%, which is similar to prior reports.10-12 
With regard to PPI use, prior studies suggested that PPI admin-
istration reduced the rebleeding rate to 4%; a rate lower than 
the finding of this study.5 The definition of rebleeding period 
Table 2. Endoscopic Characteristics of Patients
Variable Rebleeding (n=120) No rebleeding (n=434) p-value
Causes of bleeding 0.493
Gastric ulcer 72 (59) 255 (59)0
Duodenal ulcer 40 (33) 133 (31)0
Dieulafoy lesion 2 (2) 24 (20)
Anastomosis site after operation 3 (3) 13 (11)
Cancer bleeding 3 (3) 9 (8)
Bleeding state 0.010
Active spurting bleeding 18 (15) 30 (7)0
Active oozing bleeding 47 (39) 132 (30)0
Vessel exposure 42 (35) 215 (50)0
Clot 13 (11) 57 (13)
Size of ulcer, mma) 14.6±10.1 13.3±10.3 0.235
Therapy 0.002
Injection 63 (52) 145 (33)0
Thermal ablationba) 16 (13) 71 (16)
Clip 6 (5) 32 (7)0
Injection and thermal ablation 24 (20) 148 (34)0
Injection and clip 7 (6) 31 (7)0
Injection and thermal ablation and clip 4 (3) 6 (1)
Band ligation 0 (0) 1 (0)
Experience of endoscopic therapy 0.002
≤2 yr 73 (61) 193 (80)0
>2 yr 47 (39) 241 (20)0
Amount of epinephrine used 0.000
≤15 cc 30 (32) 167 (52)0
>15 cc 65 (68) 154 (48)0
Values are presented as mean±SD or number (%). p-value for Pearson’s χ2 test (2 by x) and the independent-samples t-test for comparison of 
continuous variables.
a)Argon plasma coagulation or electrocoagulation.
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(<7 days), selection of enrolled patients who received endoscop-
ic hemostasis, and administration method of PPI might have af-
fected the results of this study, because most prior studies used 
continuous infusion of high dose PPI with or without bolus in-
jection. Also, several of these studies included patients whose ul-
cers did not require an endoscopic therapy or rebleeding lasted 
Table 3. Multivariate Analysis of Factors for the Risk of Rebleeding
Variable p-value OR (95% CI)
Age 0.516 1.006 (0.988-1.024)
Gender (female/malea)) 0.143 0.612 (0.317-1.181)
Bleeding state
Active spurting bleedinga) 1.000
Active oozing bleeding 0.543 0.772 (0.335-1.777)
Vessel exposure 0.128 0.523 (0.228-1.204)
Clots 0.053 0.344 (0.117-1.016)
Endoscopic therapy
Injectiona) 1.000
Thermal ablationb) 0.613 002.589 (0.065-102.921)
Clip 0.116 0.279 (0.057-1.371)
Injection+thermal ablation 0.001 0.352 (0.193-0.640)
Injection+clip 0.062 0.374 (0.133-1.051)
Injection+thermal ablation+clip 0.275 02.813 (0.440-17.988)
Comobid diseases
No specific disease or medicationa) 1.000
Chronic renal failure 0.004 2.908 (1.393-6.068)
Liver cirrhosis 0.010 2.870 (1.289-6.387)
Coumadin use 0.495 1.563 (0.433-5.643)
Aspirin or clopidogrel use 0.353 1.501 (0.637-3.537)
Hemoglobin (≤9/>9 g/dLa)) 0.002 2.433 (1.376-4.305)
Experience of endoscopist (≤2/>2 yra)) 0.001 2.418 (1.402-4.144)
Amount of epinephrine used (>15/≤15 cca)) 0.001 2.570 (1.492-4.426)
OR, odds ratio; CI, confidence interval.
a)Reference category; b)Argon plasma coagulation or electrocoagulation.
Table 4. Multivariate Analysis of Factors for the Risk of Mortality
Variable p-value OR (95% CI)
Age 0.212 1.091 (0.990-1.049)
Gender (female/malea)) 0.410 0.651 (0.235-1.805)
Alcohol (yes/noa)) 0.094 0.468 (0.192-1.138)
Amount of used epinephrine (>15/≤15 cca)) 0.160 1.896 (0.777-4.625)
Operation 0.921 0.740 (0.173-3.167)
Bleeding state
Active spurting bleedinga) 1.000
Active oozing bleeding 0.812 0.868 (0.270-2.789)
Vessel exposure 0.021 0.192 (0.047-0.779)
Clots 0.155 0.269 (0.044-1.643)
Rebleeding (yes/noa)) 0.000  6.391 (2.748-14.864)
OR, odds ratio; CI, confidence interval.
a)Reference category.
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for a short period (<3 days).13-16 Treatment with continuous PPI 
infusion is thought to be associated with a better outcome by 
improving wound healing. However, prospective studies with 
gastric pH measurements during various administration meth-
ods of PPI are needed to further explain the underlying mecha-
nism of better hemostasis.
Rebleeding after endoscopic hemostasis is associated with an 
increased risk of mortality, prolonged hospital stay, and increased 
medical expenses.3,9 In this study, endoscopic findings of active 
spurting bleeding and the presence of rebleeding was associat-
ed with poor prognosis. Chiu et al.4 reported that larger ulcers 
with stigmata and high American Society of Anesthesiologists 
(ASA) general score (grade III and IV) were important predic-
tors of recurrent bleeding after a second endoscopy. However, 
we did not check the ASA general score in this study and the re-
lation between ulcer size and rebleeding was not confirmed. 
Comorbid disease with chronic renal failure and liver cirrho-
sis were major risk factors for rebleeding in this study. A recent 
study demonstrated that dialysis patients with end stage renal 
disease were more likely to experience rebleeding than patients 
who were not on dialysis after ulcer bleeding.17 Little has been 
known about the underlying mechanisms for high risks of bleed-
ing, rebleeding, and mortality in patients with chronic renal fail-
ure. However, decreased bicarbonate secretion, abnormal co-
agulation system, or uremic platelet dysfunction could be related 
to high risk of rebleeding.17,18 Rebleeding also might be com-
mon in these patients, since most patients with renal disease 
and cirrhosis show advanced ASA status.19 In this study, 39% 
and 30% of patients with chronic renal failure and liver cirrho-
sis, respectively, experienced rebleeding after the first endoscop-
ic treatment. A careful follow up with intensive monitoring is in-
dicated, therefore, in these patients after the endoscopic therapy.
Other factors such as coumadin, aspirin, or clopidogrel use 
were not related to rebleeding. These findings are consistent 
with a recent report showing that anticoagulation use did not in-
crease the risk of rebleeding.10 The suppression of gastroduode-
nal mucosal prostaglandin synthesis is associated with the mu-
cosal damage caused by aspirin.20 Peters et al.21 suggested that 
the risk of bleeding increases with aspirin dose increase with 
or without clopidogrel. However, these studies did not report 
on the association between rebleeding and anticoagulation 
therapy. In this present study, anticoagulation therapy was 
not related to rebleeding which was similar to other prior re-
ports.4 Immediate cessation of medication after the suspicion 
of bleeding might be associated with the negative correlation.
Consideration of procedure-related factors may be impor-
tant to reduce the mortality rate due to bleeding during and/
or after endoscopic therapy. At the time of therapy, inexperi-
enced endoscopists and the need for large amounts of epi-
nephrine were also definite risk factors for rebleeding in the 
current study. We found that 61% (73/120) of the patients 
with rebleeding had endoscopic therapy by an endoscopist 
with less than 2 years of therapeutic endoscopy experience. 
In addition, 30% (219) of bleeding cases, which could not be 
controlled by ≤15 cc of epinephrine injections, rebled within 
7 days of the initial endoscopy in this study. These findings 
were unique in the current study. Therefore, more careful ap-
proaches under the expert supervision, short term follow-up 
endoscopy, and close and intensive monitoring are needed 
for patients who underwent endoscopic therapy in circum-
stances with these 2 risk conditions.
In the consensus recommendations for managing patients 
with NGIH, combination therapy was superior to single thera-
py.1,22 Thermal ablation such as APC or electrocoagulation with 
injection therapy significantly reduced rebleeding in this study 
(p<0.01), suggesting the intensive therapy using combination 
method by an expert is a primary determinant of better out-
come in patients with NGIH. 
Low hemoglobin level and active pumping bleeding at pre-
sentation were other risk factors of rebleeding. Active pump-
ing means that seeding vessel is relatively large; and low hemo-
globin level might be a result of massive arterial bleeding. As a 
result, these findings suggest that massive bleeding from a rela-
tively large vessel was positively related to rebleeding after 
endoscopic therapy and consequent poor outcomes.
The limitations of this study include the retrospective study 
design and the use of different PPI doses and administration 
methods. Therefore, prospective studies using the same PPI 
administration are needed to properly identify the risk predic-
tors for rebleeding in a larger number of patients. Currently, a 
lot of comparative studies reported the advantages of different 
PPIs, doses, treatment methods, therapy protocols, scoring sys-
tems, and costs. Therefore, new treatments for reducing rebleed-
ing should be verified over time.
In conclusion, the results of this study showed that low he-
moglobin level at presentation, chronic renal disease, liver cir-
rhosis, treatment with endoscopic injection therapy (>15 cc of 
epinephrine) or by inexperienced endoscopist were significant-
ly related to the development of rebleeding after the endoscopic 
therapy. Moreover, since rebleeding is one of the risk factors of 
mortality, close follow up with intensive monitoring is indicat-
ed in these patients after endoscopic therapy. 
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